Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TGD001 in acute ischemic stroke
ISRCTN97585476Phase 2Recruiting
- Sponsor
- TargED Biopharmaceuticals
- Start
- Mar 2026
- Modality
- Fab Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, scFv Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
Phase 2, randomised, double-blind trial of TGD001 in ischemic stroke (3 arms), sponsored by TargED Biopharmaceuticals. Primary endpoints: Symptomatic intracranial haemorrhage and Treatment-emergent adverse events. Started Mar 2026; status: recruiting.
02
Drugs
TGD001
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on ISRCTN97585476.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN97585476.